- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03441685
Strategies for Teaching Verbs
Study Overview
Status
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt Bill Wilkerson Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must use oral communication as their primary means of communication
- Must be monolingual English speakers
- Behaviorally able to attend for 20 minutes
- Children with typical development must demonstrate no more than one standard deviation below the mean on the speech and language measures
Exclusion Criteria:
- Nonverbal cognitive score less than three standard deviations below the mean (standard score of 54 below)
- Identified hearing loss or failed hearing screening
- Uncorrected vision impairment
- Motor impairment that prevents completion of study activities
- Concomitant disorders (e.g., Autism spectrum disorder)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Verb strategies
The examiner labels each target word and performs the corresponding action six times in each condition.
She elicits the target word from the participant two times per word per condition and provides feedback on accuracy each time.
In the semantic cues condition, the examiner prompts the child to perform the target action twice.
In the syntactic cues condition, instead of only saying the target word with the present progressive verb marker, the examiner uses two forms of complete sentences while performing the action (i.e., "I am X-ing," and "See.
I X.").
In the combined condition, the examiner prompts the child to perform the target action and consistently uses complete sentences.
|
Verb Learning Session Teaching phase. The examiner labels each target word and performs the action 6 times in each condition. She elicits the target word from the participant 2 times per word per condition and provides feedback on accuracy. Testing phase. Receptive probes are administered after every 2 words are taught. Expressive probes are at the end of the condition. For receptive probes, the examiner asks the participant to identify novel verbs and for expressive probes, the examiner asks the child to label the novel action. Testing after 2 items is designed to decrease memory load. Participants have a brief break between conditions. Data are collected on: a) child responses on standardized assessments, (b) responses to verb learning probes, (c) parent responses to intake form, and (d) relevant medical history from electronic medical record. None of the above procedures present more than minimal risk to participants or research staff. Vanderbilt IRB approved all procedures. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent accuracy identifying taught words
Time Frame: From date of initial evaluation to focused intervention session, up to 1 month
|
Participants are asked to receptively identify novel verbs by selecting the video of the named verb from a field of two.
|
From date of initial evaluation to focused intervention session, up to 1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent accuracy labeling taught words
Time Frame: From date of initial evaluation to focused intervention session, up to 1 month
|
After the teaching episodes participants are asked to label novel verbs expressively
|
From date of initial evaluation to focused intervention session, up to 1 month
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 172058
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Down Syndrome
-
Rachel G. Greenberg, MD, MB, MHSEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsNot yet recruitingHyperactivity in Children With Down Syndrome | Impulsivity in Children With Down SyndromeUnited States
-
Riphah International UniversityCompletedDown S SyndromePakistan
-
Hoffmann-La RocheCompletedHealthy Volunteer, Down SyndromeUnited Kingdom
-
Cairo UniversityCompleted
-
Institute of Child HealthCompleted
-
Vanderbilt University Medical CenterNational Institute on Deafness and Other Communication Disorders (NIDCD)RecruitingSpeech Intelligibility Intervention in Down SyndromeUnited States
-
Marmara UniversityCompletedStair up and Down, Amputation | Amputation,Stair up and DownTurkey
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMyeloid Proliferations Associated With Down SyndromeUnited States, Canada, Australia, Puerto Rico
-
Eastern Mediterranean UniversityCompletedDown Syndrome, Trisomy 21Cyprus
-
Institut Jerome LejeuneFondation Jérôme LejeuneCompletedDown Syndrome With and Without Auto Immune AbnormalitiesFrance